A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

HIV-1-infection Clinical Trial

Official title:

A Proof of Concept Study to Evaluate the Safety and Efficacy of UB-421 in Combination With Chidamide for Reduction of HIV Reservoir as Compared to UB-421 Alone in ART Stabilized HIV-1 Patients Who Undergo ART Interruption

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04985890
• Other study ID #: UBP-A230-HIV
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: December 2027

Study information

• Verified date: August 2022
• Source: UBP Greater China (Shanghai) Co., Ltd
• Contact: Linda Shih, MSc
• Phone: +886 36684800
• Email: linda.shih[@]unitedbiopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption.

• To evaluate the safety and tolerability of UB-421 combined with chidamide among HIV-1 suppressed patients who undergo short-term ART interruption.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects are eligible to be included in the study only if ALL of the following criteria apply:

1. HIV-1 sero-positive, with documented HIV-1 infection by official, signed, written history.

2. Male with body weight = 50 kg or female with body weight = 45 kg, aged 18 years or older.

3. Have been receiving at least (?) 2 nucleoside/ nucleotide reverse transcriptase inhibitors (NRTI) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI, either boosted or un-boosted), integrase strand transfer inhibitor (INSTI) or entry inhibitor (EI) for more than 1 years.

4. Have more than 2 different alternative options of optimized ART regimen.

5. HIV-1 plasma viral load (VL) level well suppressed below 50 RNA copies/mL for at least (?) 12 months.

6. No breastfeeding or pregnancy for women.

7. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (eg, barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectable, combinational oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test.

8. Subjects must sign the informed consent before undergoing any study procedures.

Exclusion Criteria:

Subjects meeting ANY of the following criteria will be excluded from the study:

1. Subjects with active systemic infections, except for HIV-1, that the investigator feels the infections may confound evaluation and treatment for HIV-1.

2. Any acquired AIDS-defining illness such as non-Hodgkin's lymphoma or Kaposi's sarcoma according to the U.S. Centers for Disease Control and Prevention Classification System for HIV-1 Infection within the past 12 months .

3. Any documented CD4+ T cell count < 200 cells/mm3 within the past 12 weeks .

4. Any exposure to a monoclonal antibody within the past 12 weeks.

5. Any significant diseases (other than HIV-1 infection) or clinically significant findings, that, in the Investigator's opinion, would preclude the subject from well participation or confound the assessment of study objectives.

6. Current receiving treatment regimen for Diabetes, hepatitis B, hepatitis C, or latent tuberculosis.

7. History of anaphylaxis to any monoclonal antibodies or HDAC inhibitor agents.

8. Received blood transfusion or hematopoietic growth factor treatment, any vaccine, or a compound with HDAC inhibitor activity (such as valproic acid) recently.

9. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior to V1.

10. More than one change of ART regimen because of the inability to achieve or maintain suppression of viral replication to an HIV-1 RNA level < 200 copies/mL within the past 12 months

11. Receipt of any other investigational study agent(s) within 90 days.

12. Experienced urticaria in recent 6 months or ongoing or unresolved skin problems with rash-like symptoms .

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Biological:
• UB-421
10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy

Other:
• UB-421+chidamide
10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
UBP Greater China (Shanghai) Co., Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV-1 Total DNA levels	The change in HIV-1 Total DNA from baseline after the study drug administration.	Post-treatment weeks up to 48 weeks
Secondary	HIV-1 Total DNA levels	The changes in HIV-1 Total DNA levels during the study	Post-treatment weeks up to 48 weeks
Secondary	Treatment related TEAE	The incidence of Grade 3 or higher grade drug-related treatment-emergent adverse events (TEAE)	through study completion, an average of 0.5 year
Secondary	Viral suppression	Descriptive analysis of loss of viral suppression (HIV-1 VL> 50 copies/ml) during the study period.	Post-treatment weeks up to 48 weeks
Secondary	The number of adverse subjects	The number of adverse subjects leading to discontinuation of UB 421 or Chidamide.	Post-treatment weeks up to 48 weeks